業界のプレスリリース
GEA supplies separator plant for trials, upscaling and production of a possible future corona vaccine to China
30 Apr 2020
In the battle against the Covid-19 virus, technology leader GEA announces an order to supply a separator plant for vaccines to China. The plant will be used for clinical samples and later for the actual production process for the manufacture of a possible future corona vaccine.
GEA centrifuge package with fully automatic SIP: Steam-sterilizable and completely sealed, designed for maximum biosafety and containment. (Photo: GEA)
As the technology leader for steam-sterilizable separators in pharmaceutical production, GEA is making an important contribution to the fight against the corona virus Sars-CoV-2 with its technology and competence in the field of separators.
Steam sterilizable and designed to the highest hygienic standards
The GEA pharma skid unit ensures the so important biocontainment to prevent cross-contamination. A hermetically closed plant concept prevents the product from coming into contact with the environment. The separator system achieves maximum yield due to its gentle product treatment and high separation efficiency. The separator system is supplied in steam-sterilizable design (SIP at 2.5 bar/137°C) to ensure aseptic processing of pharmaceutical products. These systems also have the function of fully automatic on-site cleaning (CIP, "Clean-in-Place") in hygienic, highly polished design. The hydrohermetic inlet system for shear-sensitive products is patented by GEA. The plant is driven by a 3-phase alternating current motor. All parts in contact with the product are made of high-alloy stainless steels. The seals comply with FDA and USP Class VI requirements.
GEA: Solutions for vaccine production
The challenge in vaccine production is the competence to translate the findings and results of laboratory research into large-scale industrial production in such a way that they fully meet the complex requirements of biotechnological processes. Together with customers, GEA develops processes that not only allow upscaling from laboratory scale to production scale, but also ensure that the quality, safety and efficacy of each individual batch of vaccine can be checked and reproduced at any time.
GEA is a partner for practically all major global vaccine manufacturers. Separation technology using separators is one of the key technologies in vaccine production.
GEA also offers complete systems and process lines for vaccine production.
Media Relations
GEA Group Aktiengesellschaft
Peter-Müller-Str. 12
40468
Düsseldorf
Germany
+49 211 9136-0
GEA の概要
GEA は、世界レベルの食品製造プロセス技術を有するとともに、乳業、飲料、パーソナル・ホームケア、化学など食品以外の幅広い分野にも実績があり、2019年度の連結売上高は約49億ユーロとなりました。
